Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Phase 2 Trial of HinsBet Begins

By Drug Discovery Trends Editor | June 28, 2011

Adocia SAS, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced the launch of its second clinical trial for the development of HinsBet, its fast-acting human insulin.

The company completed a Phase 1 study in March on healthy volunteers showing that the action of HinsBet is as fast as that of NovoLog and has less variability. The positive clinical results obtained with HinsBet during the Phase 1 study have permitted to quickly start a second study of Phase 2a on 20 type 1 diabetics.
 
The Phase 2a study is double-blinded, under euglycemic clamp, and aims to compare variabilities of HinsBet and NovoLog with three repeated injections of each product to each patient.
 
“We expect this study to confirm HinsBet’s similar efficacy on type 1 diabetics compared with Novo Nordisk’s fast-acting insulin analog which is the market leader,” said Dr Gérard Soula, president and CEO at Adocia.
 
Adocia has developed HinsBet using its BioChaperone library of polysaccharides modified with naturally occurring molecules. BioChaperone is designed to form a reversible molecular complex with therapeutic proteins in order to solubilize and stabilize these proteins and to control their delivery.
 
”Adocia’s BioChaperone boosts absorption of insulins, human as well as analogs,” said Dr Olivier Soula, vice president and R&D director at Adocia. “This has already been proved in the clinic in humans with human insulin. Moreover, the absorption rate with NovoLog has been doubled after subcutaneous injection using a pig model.”
 
As a result of the promising clinical development, the company is actively seeking pharmaceutical partners in order to develop its innovative insulin formulations.

Date: June 24, 2011
Source: Adocia SAS 


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50